Kidney failure chronic, renal dialysis, inflammation, oxidative stress, dyslipidemias, body composition, fatty acids,
Conditions
Interventions
Intervention: 21 patients daily supplementation with 5 mL of baru oil, 10 gelatin capsules daily (5 before lunch and 5 before dinner), duration of 12 weeks in chronic renal patients under hemodialysis
Dietary supplement
A09.371.061
Sponsors
Universidade Federal de Goiás
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - CAPES
Eligibility
Age
25 Years to 70 Years
Inclusion criteria
Inclusion criteria: Chronic renal patients undergoing adequate hemodialysis treatment (Kt / V superior at 1.2), via arteriovenous fistula, of both sexes, aged between 25 and 70 years.
Exclusion criteria
Exclusion criteria: Patients with a history of acute myocardial infarction in the last six months; recent hospitalization (less than three months from the start of the study), decompensated diabetes, presence of thyroid dysfunction, patients with acute infections and patients who presented food intolerance to baru or allergy to any oilseed.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The present study expects a reduction of 5% in the percentage of body fat (body composition).;The present study is expected to improve inflammation with a 10% reduction in C-reactive protein (CRP), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) concentrations with a concomitant increase of 10 % on IL-10.;The present study is expected to improve oxidative stress markers with a 10% increase in concentrations of superoxide desmutase (SOD), catalase (CAT) and glutathione peroxidase (GPx).;The present study is expected to improve dyslipidemia with a 10% reduction of LDL-c, total cholesterol and triglycerides with a simultaneous increase of 10% of HDL-c.;The present study is expected to improve the profile of blood fatty acids with a 5% increase in concentrations of polyunsaturated fatty acids and monounsaturated fatty acids with simultaneous decrease of circulating saturated fatty acids. | — |
Secondary
| Measure | Time frame |
|---|---|
| With the achievement of the primary outcomes, a reduction of 5% of the cardiovascular risk that these patients are expected is expected. | — |
Countries
Brazil
Contacts
Public ContactRaquel schincaglia
Universidade Federal de Goiás
Outcome results
None listed